Trending...
- Turbo vs. Experts: Tracking OddsTrader's AI Performance at the NFL's Midpoint
- Outreaching.io Appoints Rameez Ghayas Usmani as CEO, Recognized as Best HARO Link Building Expert in the United States
- Entrigue Magazine LLC Announces Strategic Media Partnership with Reewind Network LLC
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.
SAN DIEGO - PennZone -- About John Burd, PhD:
Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc. In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes. The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications. In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.
Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes. In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million. In 2020 DexCom had a market cap of over $40 billion. From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.
Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market. LXN was sold to Johnson and Johnson in 2000.
More on The PennZone
Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance. MAST Immunosystems was purchased by Hitachi Chemical in 1997. Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).
Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin. In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.
Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
JOHN F. BURD, Ph.D.
Founder & CEO Lysulin, Inc and Wonder Spray, llc.
More on The PennZone
4930 Bradshaw Court, San Diego, CA 92130
Phone: 619-992-2873
Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)
Learn more about Dr. Burd's products below...
Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8
Lysulin video: https://www.youtube.com/watch?v=PK3CkMty6RE
Running A1c test: https://tinyurl.com/y379jbla
Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos
Follow Burd's PR News at http://Beneficience.com
MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd
Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc. In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes. The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications. In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.
Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes. In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million. In 2020 DexCom had a market cap of over $40 billion. From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.
Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market. LXN was sold to Johnson and Johnson in 2000.
More on The PennZone
- Together We Dance Foundation Thrives Through Donor and Athlete Support
- Platinum Plumbing Launches First Veteran Hot Water Heater Giveaway to Honor Local Heroes
- Cuts Costs & Boosts Profits with the First Major Upgrade in 30 YEARS Replacing Rotary Lasers and Historic Clear Tube Altimeter Bubbles
- Inframark Expands Its Specialized Automation and Intelligence Capabilities, Adds Dmytryka Jacobs Engineers
- Sustainable Santa Returns to Old Sacramento
Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance. MAST Immunosystems was purchased by Hitachi Chemical in 1997. Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).
Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products. He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin. In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.
Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
JOHN F. BURD, Ph.D.
Founder & CEO Lysulin, Inc and Wonder Spray, llc.
More on The PennZone
- Upcoming Launch of Retail Crypto Cloud Mining Platform with Daily Rewards in a Transparent Revenue-Share Model: iMD Companies, Inc. Stock Symbol: ICBU
- BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers
- CRH Healthcare Opens 100th Urgent Care Clinic with Second Peachtree Immediate Care Location in Covington
- COHN Named Colorado State-Approved Vendor for Advertising & Marketing Services
- The Kryder Law Group, LLC Report Reveals Commercial Air Travel Is Safer Than You Think
4930 Bradshaw Court, San Diego, CA 92130
Phone: 619-992-2873
Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)
Learn more about Dr. Burd's products below...
Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8
Lysulin video: https://www.youtube.com/watch?v=PK3CkMty6RE
Running A1c test: https://tinyurl.com/y379jbla
Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos
Follow Burd's PR News at http://Beneficience.com
MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd
Source: Beneficience.com Legacy PR
0 Comments
Latest on The PennZone
- Uk Financial Ltd Provides Investors Of Maya Preferred & Mayacat Instructions For Upcoming First Ever Listing Of Both Erc-3643 "SEC-Ready" Tokens
- Kaufman Development and Daniel Kaufman Ventures Announce Strategic Expansion Into Data Centers and AI Infrastructure Across the United States
- Bent Danholm Lists Modern Lakefront Estate in Winter Garden's Twinwaters Community
- Operational Agility in High Demand: FOCUS Expands to Serve a Changing Insurance Market
- Bahamas Import Assistant Launches Same-Day Pet Permit Service Under BAHFSA's 2024 Expansion
- Liftoff Enterprises Launches Liftoff Spotlight,™ A Nationally Broadcast Platform Turning Conversations Into Revenue
- From November 24th to 27th, Fuqing Invites You to Join Us at BIG 5 to Jointly Build a New Future for Middle Eastern Architecture
- Dispelling Holiday Suicide Myth: CDC Data Shows Suicide Rates Lowest in December; International Survivors of Suicide Day Emphasizes Need for Action
- Stratum Nutrition's OVOLUX™ Named 2025 "Collagen Ingredient of the Year" by Beauty Innovation Awards
- Sons of Liberty Museum Unveils "America at 250" Mobile Exhibit on Veterans Day 2025
- Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
- Bent Danholm Releases New Video Breaking Down the Rising Debate Over 50-Year Mortgages
- New Smile Now Introduces RAYFace 3D Scanner to Advance Digital Surgery
- Ali Alijanian, DDS Featured in The Profitable Dentist Magazine
- "Meet the Eatmons" Offer Financial Advice ahead of the Holidays
- CCHR: Study Finds Involuntary Commitment Fails to Prevent Suicide, Raises Risk
- Slotozilla's Q3 2025: SBC Lisbon Outcomes and Partnership Expansion
- Historic Announcement for the Global Car Rental Industry
- Siembra Brings 18 Latinx Artists Together in Brooklyn Exhibition
- Gramercy Tech Launches StoryStream





